These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 26892041

  • 1. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child.
    Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, Tebben PJ.
    Osteoporos Int; 2016 Jul; 27(7):2379-2382. PubMed ID: 26892041
    [Abstract] [Full Text] [Related]

  • 2. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A.
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
    Brown JJ, Zacharin MR.
    J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
    [Abstract] [Full Text] [Related]

  • 4. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy.
    Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M.
    Joint Bone Spine; 2017 Mar; 84(2):213-215. PubMed ID: 27939801
    [Abstract] [Full Text] [Related]

  • 5. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX.
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [Abstract] [Full Text] [Related]

  • 6. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002 Aug; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

  • 7. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.
    N Engl J Med; 2012 Nov 01; 367(18):1714-23. PubMed ID: 23113482
    [Abstract] [Full Text] [Related]

  • 8. Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.
    Kulkarni P, Cushman T, Donthireddy V, Rao S.
    BMJ Case Rep; 2016 Feb 03; 2016():. PubMed ID: 26843222
    [Abstract] [Full Text] [Related]

  • 9. Seizures associated with zoledronic acid for osteoporosis.
    Tsourdi E, Rachner TD, Gruber M, Hamann C, Ziemssen T, Hofbauer LC.
    J Clin Endocrinol Metab; 2011 Jul 03; 96(7):1955-9. PubMed ID: 21508139
    [Abstract] [Full Text] [Related]

  • 10. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.
    Kaur U, Chakrabarti SS, Gambhir IS.
    Curr Drug Saf; 2016 Jul 03; 11(3):267-9. PubMed ID: 27113952
    [Abstract] [Full Text] [Related]

  • 11. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 12. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul 03; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
    Tian Y, Wang R, Liu L, Ma C, Lu Q, Yin F.
    BMC Musculoskelet Disord; 2016 Feb 11; 17():72. PubMed ID: 26867651
    [Abstract] [Full Text] [Related]

  • 15. Bilateral Acute Anterior Uveitis and Conjunctivitis following Intravenous Zoledronic Acid.
    Chatterjee S, Agrawal D.
    J Assoc Physicians India; 2017 Jul 11; 65(7):110-111. PubMed ID: 28792180
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA.
    J Clin Endocrinol Metab; 2015 Nov 11; 100(11):4163-71. PubMed ID: 26308295
    [Abstract] [Full Text] [Related]

  • 18. Drug-induced dermatomyositis after zoledronic acid.
    Tong PL, Yu LL, Chan JJ.
    Australas J Dermatol; 2012 Nov 11; 53(4):e73-5. PubMed ID: 23157790
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Effects of zoledronic acid on osteoporosis patients in Japan.].
    Tanaka S.
    Clin Calcium; 2017 Nov 11; 27(2):257-261. PubMed ID: 28123128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.